K36 Therapeutics, Inc.
Clinical trials sponsored by K36 Therapeutics, Inc., explained in plain language.
-
First-of-its-Kind pill targets Hard-to-Treat blood cancer
Disease control Recruiting nowThis early-stage study is testing a new oral medication called KTX-1001 in adults with multiple myeloma that has returned or stopped responding to standard treatments. The main goals are to find the safest and most effective dose and to see how well the body handles the drug. Res…
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New drug trial offers hope for men with aggressive prostate cancer
Disease control Recruiting nowThis is the first study in people testing a new drug called KTX2001 for advanced prostate cancer that has spread and stopped responding to standard hormone treatments. Researchers will give the drug alone and combined with an existing medication (darolutamide) to about 144 men to…
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC